A deal to find investors to buy a portfolio of biotech start-ups held in the LF Equity Income fund for £550m has fallen through, according to reports.
PJT Park Hill, the company tasked with offloading the illiquid part of the fund's portfolio, formerly run by Neil Woodford, gave a period of exclusivity to WG Partners to assemble a group of investors interested in buying a large portion of the companies, The Sunday Times reported. WG Partners, an investment bank that specialises in arranging life sciences deals, was said to have trawled both America and China to find investors, but is understood to have missed the deadline set by Park Hill. The deal, which is understood to have included 20 companies, was worth £550m and accounted for...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes